Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BCLI | Common Stock | Award | $0 | +12K | +22.5% | $0.00 | 65.3K | Dec 10, 2021 | Direct | F1 |
Id | Content |
---|---|
F1 | Shares acquired are shares of restricted stock awarded effective November 11, 2020 in connection with the Company's 2020 Annual Meeting of Stockholders, pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director of Brainstorm Cell Therapeutics on each vesting date. |